• +1-646-491-9876
    • +91-20-67278686

    Search

    Exocrine Pancreatic Insufficiency-Pipeline Review H1 2017

    Exocrine Pancreatic Insufficiency-Pipeline Review H1 2017

    • Report Code ID: RW0001834392
    • Category Pharmaceuticals
    • No. of Pages 42
    • Publication Month Jun-17
    • Publisher Name Global Markets Direct
    Exocrine Pancreatic Insufficiency - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Exocrine Pancreatic Insufficiency - Pipeline Review, H1 2017, provides an overview of the Exocrine Pancreatic Insufficiency (Gastrointestinal) pipeline landscape.

    Exocrine pancreatic insufficiency (EPI) is a condition characterized by deficiency of the exocrine pancreatic enzymes, resulting in the inability to digest food properly, or maldigestion. Symptoms include diarrhea, loose, oily stools with unabsorbed fat (steatorrhea) , vitamin deficiencies, loss of appetite, and unexplained weight loss. Treatment includes pancreatic enzyme replacement therapy (PERT) and lifestyle modifications.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Exocrine Pancreatic Insufficiency - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Exocrine Pancreatic Insufficiency (Gastrointestinal) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Exocrine Pancreatic Insufficiency (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Exocrine Pancreatic Insufficiency and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 3 and 1 respectively.

    Exocrine Pancreatic Insufficiency (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Exocrine Pancreatic Insufficiency (Gastrointestinal) .
    - The pipeline guide reviews pipeline therapeutics for Exocrine Pancreatic Insufficiency (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Exocrine Pancreatic Insufficiency (Gastrointestinal) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Exocrine Pancreatic Insufficiency (Gastrointestinal) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Exocrine Pancreatic Insufficiency (Gastrointestinal)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Exocrine Pancreatic Insufficiency (Gastrointestinal) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Exocrine Pancreatic Insufficiency (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Exocrine Pancreatic Insufficiency - Overview
    Exocrine Pancreatic Insufficiency - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Products under Development by Companies
    Exocrine Pancreatic Insufficiency - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Exocrine Pancreatic Insufficiency - Companies Involved in Therapeutics Development
    Anthera Pharmaceuticals Inc
    Celleron Therapeutics Ltd
    Cilian AG
    Laboratoires Mayoly Spindler SAS
    Nordmark Arzneimittel GmbH & Co KG
    Exocrine Pancreatic Insufficiency - Drug Profiles
    burlulipase - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Cilase - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CXD-101 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    liprotamase - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MS-1819 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Exocrine Pancreatic Insufficiency - Dormant Projects
    Exocrine Pancreatic Insufficiency - Discontinued Products
    Exocrine Pancreatic Insufficiency - Product Development Milestones
    Featured News & Press Releases
    May 15, 2017: Anthera Announces First Patient Screened in RESULT Pivotal Phase 3 Clinical Study of Sollpura
    Apr 11, 2017: AzurRx Provides Update on MS1819 Phase II Trial
    Dec 21, 2016: AzurRx BioPharma Announces First Three Patients Included in Phase IIa Study with MS1819-SD for Endocrine Pancreatic Insufficiency
    Nov 17, 2016: AzurRx BioPharma and Mayoly-Spindler Announce Initiation of Phase II Clinical Trial of MS1819-SD for Exocrine Pancreatic Insufficiency in Chronic Pancreatitis Patients
    Jun 28, 2016: Anthera Provides Clinical Program Update for Sollpura
    Mar 19, 2015: Anthera Announces $3 Million Research Award from Cystic Fibrosis Foundation Therapeutics for Development of Sollpura - a Novel Enzyme Therapy
    Nov 20, 2014: Anthera and Patheon Sign Manufacturing Agreement for Liprotamase Phase III Registration Trial
    Aug 01, 2012: Cilian Receives €1m Grant For Development Of Cilase
    Apr 15, 2011: Lilly Receives Complete Response Letter From FDA For Liprotamase For Treatment Of Exocrine Pancreatic Insufficiency
    Jan 12, 2011: Lilly Announces FDA Panel Recommendation For Liprotamase
    Jun 22, 2010: Protea Biosciences And Mayoly-­Spindler Announce Human Clinical Trial For New Biopharmaceutical.
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Exocrine Pancreatic Insufficiency, H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Exocrine Pancreatic Insufficiency - Pipeline by Anthera Pharmaceuticals Inc, H1 2017
    Exocrine Pancreatic Insufficiency - Pipeline by Celleron Therapeutics Ltd, H1 2017
    Exocrine Pancreatic Insufficiency - Pipeline by Cilian AG, H1 2017
    Exocrine Pancreatic Insufficiency - Pipeline by Laboratoires Mayoly Spindler SAS, H1 2017
    Exocrine Pancreatic Insufficiency - Pipeline by Nordmark Arzneimittel GmbH & Co KG, H1 2017
    Exocrine Pancreatic Insufficiency - Dormant Projects, H1 2017
    Exocrine Pancreatic Insufficiency - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Exocrine Pancreatic Insufficiency, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Targets, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Anthera Pharmaceuticals Inc
    Celleron Therapeutics Ltd
    Cilian AG
    Laboratoires Mayoly Spindler SAS
    Nordmark Arzneimittel GmbH & Co KG

    Request for Sample

    Report Url https://www.reportsweb.com//exocrine-pancreatic-insufficiency-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//exocrine-pancreatic-insufficiency-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//exocrine-pancreatic-insufficiency-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments